Biotech News & Trading Forum: Community User: Weedmaster

🙂👍✌👌

Ein ganz großes Dankeschön geht auch an dich mein Freund. 😊👍

Danke @ alle die hier mitmachen und den Threat so wertvoll machen! 👍

...so viele schöne Sachen! 👍😁

Danke Bio! 😉

👍😃

Tocagen heute fast 10% 😅

(ADMP) Kurs: $0.55 / Marktkap: $34 M / Cash :$17 M / FDA Entscheidung am 31.OCTOBER (behandlung von Opioid Übderosis) ,, Firma hat bereits ein attraktives Produkt amMarkt welches von Novartis vermarketet wird . Potentieller 10 bagger hier ,,,Präsentation http://ir.adamispharmaceuticals.com/static-files/63eff6dd-0286-457e-a959-920540f0cdb1 ZIMHI (naloxone) Injection On March 14, 2019, Adamis announced that the FDA had accepted the company’s New Drug Application (NDA) for review and provided a target agency action date (PDUFA) of October 31, 2019. The company believes that if approved, ZIMHI could be an important part of the solution to this growing health crisis of opioid overdose. The company is in discussions with several potential partners for ZIMHI with the goal of finalizing a commercial distribution agreement for the U.S. prior to a potential approval. Marketed Drug: SYMJEPI (epinephrine) injection Indication-Anaphylaxis Addressable Market -$1.5 billion Launched–January 2019 First products using patented, FDA-approved injection device Both doses (0.3mg and 0.15mg) are FDA approved Sandoz a division of Novartis –commercial partner in U.S. Commercial deal terms –50% of net profits, upfront fee and potential performance-based milestone payments

Bio Path 😁👍 hoffe auf einen nachhaltigen Anstieg.

@Gottsbrain, danke für die Quelle habe mich mal registriert. Wundert mich aber das der Kurs nachbörslich noch um 16% steigt. Kann natürlich auch eine Falle sein.

https://www.genomeweb.com/sequencing/bionano-genomics-amends-stock-warrant-offering Hört sich für mich nicht gerade bullish an.🤔

Was haltet Ihr von $BNGO? Die hatten in den letzten Tagen einen guten Lauf mit sehr guten Volumen. Viel Info. kann ich da leider nicht dienen. Da kam zwar noch eine Verwässerung ins Spiel ist aber nach Handelsschluss nochmal kräftig angezogen. Da könnte nochmal ordentlich was gehen, scheint ordentlich Bewegung drin zu sein.

AGRX – Agile Therapeutics Inc. Twirla Contraceptive patch CRLs issued 2013 and 2017. New PDUFA date November 16, 2019. Advisory Committee Meeting October 30, 2019. ARVN – Arvinas Inc. ARV-110 Castration-resistant prostate cancer (CRPC) Phase 1 initial data to be presented at the Targeted Protein Degradation Summit October 23, 2019 at 11:30 AM. CLSN – Celsion Corporation ThermoDox - OPTIMA Hepatocellular carcinoma - liver cancer Phase 3 interim efficacy analysis due by mid-October 2019 with second interim analysis due 1H 2020. SYRS – Syros Pharmaceuticals Inc. SY-1425 Acute Myeloid Leukemia / Myelodysplastic Syndrome Phase 2 updated data due October 24, 2019 at ESH in newly diagnosed AML patients.

http://www.foamix.com/news-releases/news-release-details/foamix-receives-fda-approval-amzeeqtm-topical-minocycline

Ich habe für Q4 noch etwas interessantes. Axovant Gene Therapies Ltd.  Three Q4'19 Catalysts For Axovant Summary AXGT expects to report data from three trials in Q4'19. AXGT's gene therapy for Parkinson's disease has already produced promising data earlier this year. Upcoming data in Parkinson's disease comes from patients treated with a higher dose. Axovant Gene Therapies (AXGT) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article. AXGT's three clinical programs include a trial of AXO-LENTI-PD, a gene therapy for Parkinson's disease, a trial on AXO-AAV-GM2, a gene therapy for GM2 gangliosidosis and a trial on AXO-AAV-GM1, a gene therapy for GM1 gangliosidosis. https://seekingalpha.com/symbol/AXGT

Foamix halted pending News,pdufa 20.10.